Antonio Arévalo-Genicio
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Antonio Arévalo-Genicio has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Maria Llistosella
Primary Health Care, Consorci Sanitari de Terrassa, Terrassa, Spain
5 shared publications - Ramon Roca-Puig
Research and Innovation, Hospital de Terrasa-Hospital Universitari (CST), Carretera de Torrebonica s/n, 08227 Terrassa, Spain
5 shared publications - Anna Puigdellívol-Sánchez
Laboratory of Surgical Neuroanatomy (LSNA), Human Anatomy and Embryology Unit, Faculty of Medicine and Health Sciences, Universitat de Barcelona, 08036 Barcelona, Spain
4 shared publications - M. Carmen García-Arqué
Primary Health Care, CAP St. Genís (CST), Carrer Miquel Mumany 11, 08191 Rubí, Spain
4 shared publications - Marta Gragea-Nocete
Primary Health Care, CAP St. Llàtzer–Centre Universitari (CST), c/de la Riba 62, 08221 Terrassa, Spain
4 shared publications - Cristina Pérez-Díaz
Primary Health Care, CAP St. Genís (CST), Carrer Miquel Mumany 11, 08191 Rubí, Spain
3 shared publications
Latest Publications
- 25 March 2026
- Published by Taylor & Francis in Health Psychology Review
- Vol. 20 (3) , 1-22
Psychological interventions for individuals with long COVID: a systematic review and meta-analysis
Introduction: Long COVID involves a variety of persistent symptoms after initial SARS-CoV-2 infection, affects multiple functional areas and requires multidisciplinary treatment. Objective: This study aimed to explore the available evidence about psychological interventions for individuals with long COVID and their effectiveness in reducing some prevalent symptoms, such as fatigue, anxiety or depression, among others, and improving patient quality of life. Methodology: A systematic review and meta-analysis were conducted following the PRISMA 2020 guidelines. Two independent reviewers performed study selection and data extraction using Web of Science, Scopus, and PubMed databases prior to March 2024. Data synthesis was performed via random-effects meta-analysis, with heterogeneity assessed using the I2 statistic. Results: Of the 1041 articles obtained, 19 were included in the systematic review and 14 in the meta-analysis. Results showed significant reductions in symptoms of anxiety [SMD = -0.64 (95% CI: -1.18 to -0.10)], depression [SMD = -0.41 (95% CI: -0.73 to -0.10)] and fatigue [SMD = -1.37 (95% CI: -2.48 to -0.26)]. Significant improvements were only registered in self-perceived health-related quality of life [SMD = 7.59 (95% CI: 3.70-11.48)]. Conclusion: Results showed improvements in anxiety, depression or fatigue, highlighting the potential role of psychological interventions in patient recovery.
- 25 March 2026
- Published by Taylor & Francis in Health Psychology Review
- Vol. 20 (3) , 1-22
Psychological interventions for individuals with long COVID: a systematic review and meta-analysis
Introduction: Long COVID involves a variety of persistent symptoms after initial SARS-CoV-2 infection, affects multiple functional areas and requires multidisciplinary treatment. Objective: This study aimed to explore the available evidence about psychological interventions for individuals with long COVID and their effectiveness in reducing some prevalent symptoms, such as fatigue, anxiety or depression, among others, and improving patient quality of life. Methodology: A systematic review and meta-analysis were conducted following the PRISMA 2020 guidelines. Two independent reviewers performed study selection and data extraction using Web of Science, Scopus, and PubMed databases prior to March 2024. Data synthesis was performed via random-effects meta-analysis, with heterogeneity assessed using the I2 statistic. Results: Of the 1041 articles obtained, 19 were included in the systematic review and 14 in the meta-analysis. Results showed significant reductions in symptoms of anxiety [SMD = -0.64 (95% CI: -1.18 to -0.10)], depression [SMD = -0.41 (95% CI: -0.73 to -0.10)] and fatigue [SMD = -1.37 (95% CI: -2.48 to -0.26)]. Significant improvements were only registered in self-perceived health-related quality of life [SMD = 7.59 (95% CI: 3.70-11.48)]. Conclusion: Results showed improvements in anxiety, depression or fatigue, highlighting the potential role of psychological interventions in patient recovery.
- Open Access
Long COVID and Reduced Thrombosis in Antihistamine-Treated Patients: An Observational Study in the Metropolitan Area of Barcelona
Background: Early evidence from a nursing home in Yepes (Toledo, Spain) indicated that antihistamines combined with azithromycin prevented deaths and hospitalizations during the first COVID-19 wave. Subsequent data from the Consorci Sanitari de Terrassa (CST) showed that patients chronically taking antihistamines had significantly reduced hospital admissions and mortality. However, a concerning rise in long COVID incidence (2–5%) after the third infection and a doubling of thrombosis rates in patients over 60 were observed. Objective: This study aimed to determine whether chronic antihistamine prescription is associated with a reduction in long COVID syndrome and thrombotic events. Methods: We analyzed anonymized data from the CST population (n = 192,651 as of March 2025). Variables included age, gender, chronic antihistamine use, number of chronic treatments (nT), COVID-19 vaccination status, SARS-CoV-2 infection history, long COVID (LC) incidence, and aggregated thrombotic events. Odds ratios (OR) were calculated using chi-square tests. Results: The prevalence of LC increased progressively with successive infections in the non-antihistamine group. No significant differences were found with the antihistamine group, which presented no LC cases among the 52 patients with three documented infections. Thrombotic events were significantly less frequent in antihistamine users with at least one chronic prescription (p < 0.0001). Conclusions: Results suggest a protective effect of antihistamines against thrombotic events. While confirmation via multicenter, randomized trials is needed, a pragmatic approach using antihistamines could be considered for symptomatic patients in the early stage of infection.
Open AccessLong COVID and Reduced Thrombosis in Antihistamine-Treated Patients: An Observational Study in the Metropolitan Area of Barcelona
Background: Early evidence from a nursing home in Yepes (Toledo, Spain) indicated that antihistamines combined with azithromycin prevented deaths and hospitalizations during the first COVID-19 wave. Subsequent data from the Consorci Sanitari de Terrassa (CST) showed that patients chronically taking antihistamines had significantly reduced hospital admissions and mortality. However, a concerning rise in long COVID incidence (2–5%) after the third infection and a doubling of thrombosis rates in patients over 60 were observed. Objective: This study aimed to determine whether chronic antihistamine prescription is associated with a reduction in long COVID syndrome and thrombotic events. Methods: We analyzed anonymized data from the CST population (n = 192,651 as of March 2025). Variables included age, gender, chronic antihistamine use, number of chronic treatments (nT), COVID-19 vaccination status, SARS-CoV-2 infection history, long COVID (LC) incidence, and aggregated thrombotic events. Odds ratios (OR) were calculated using chi-square tests. Results: The prevalence of LC increased progressively with successive infections in the non-antihistamine group. No significant differences were found with the antihistamine group, which presented no LC cases among the 52 patients with three documented infections. Thrombotic events were significantly less frequent in antihistamine users with at least one chronic prescription (p < 0.0001). Conclusions: Results suggest a protective effect of antihistamines against thrombotic events. While confirmation via multicenter, randomized trials is needed, a pragmatic approach using antihistamines could be considered for symptomatic patients in the early stage of infection.
- Open Access
- 19 December 2025
- Published by MDPI AG in Preprints.org
Long COVID and Reduced Thrombosis in Antihistamine Treated Patients: An Observational Study in the Metropolitan Area of Barcelona
Background: Early evidence from a nursing home in Yepes (Toledo, Spain) indicated that antihistamines combined with azithromycin prevented deaths and hospitalizations dur-ing the first COVID-19 wave. Subsequent data from the Consorci Sanitari de Terrassa (CST) showed that patients chronically taking antihistamines significantly reduced hos-pital admissions and mortality. However, a concerning rise in long COVID incidence (2–5%) after the third infection and a doubling of thrombosis rates in patients over 60 were observed. Objective: This study aimed to determine whether chronic antihistamine pre-scription is associated with a reduction in long COVID syndrome and thrombotic events. Methods: We analyzed anonymized data from the CST population (n=192,651 as of March 2025). Variables included age, gender, chronic antihistamine use, number of chronic treatments (nT), COVID-19 vaccination status, SARS-CoV-2 infection history, long COVID (LC) incidence, and aggregated thrombotic events. Odds ratios (OR) were calculated using chi-square tests. Results: The prevalence of LC increased progressively with successive in-fections in the non-antihistamine group. No significant differences were found with the antihistamine group, which presented no LC cases among the 52 patients with three documented infections. Thrombotic events were significantly less frequent in antihista-mine users with at least one chronic prescription (p< 0.0001). Conclusions: Results suggest a protective effect of antihistamines against thrombotic events. While confirmation via multicenter, randomized trials is needed, a pragmatic approach using antihistamines could be considered for symptomatic patients in the early stage of infection.
- 19 December 2025
- Published by MDPI AG in Preprints.org
Open AccessLong COVID and Reduced Thrombosis in Antihistamine Treated Patients: An Observational Study in the Metropolitan Area of Barcelona
Background: Early evidence from a nursing home in Yepes (Toledo, Spain) indicated that antihistamines combined with azithromycin prevented deaths and hospitalizations dur-ing the first COVID-19 wave. Subsequent data from the Consorci Sanitari de Terrassa (CST) showed that patients chronically taking antihistamines significantly reduced hos-pital admissions and mortality. However, a concerning rise in long COVID incidence (2–5%) after the third infection and a doubling of thrombosis rates in patients over 60 were observed. Objective: This study aimed to determine whether chronic antihistamine pre-scription is associated with a reduction in long COVID syndrome and thrombotic events. Methods: We analyzed anonymized data from the CST population (n=192,651 as of March 2025). Variables included age, gender, chronic antihistamine use, number of chronic treatments (nT), COVID-19 vaccination status, SARS-CoV-2 infection history, long COVID (LC) incidence, and aggregated thrombotic events. Odds ratios (OR) were calculated using chi-square tests. Results: The prevalence of LC increased progressively with successive in-fections in the non-antihistamine group. No significant differences were found with the antihistamine group, which presented no LC cases among the 52 patients with three documented infections. Thrombotic events were significantly less frequent in antihista-mine users with at least one chronic prescription (p< 0.0001). Conclusions: Results suggest a protective effect of antihistamines against thrombotic events. While confirmation via multicenter, randomized trials is needed, a pragmatic approach using antihistamines could be considered for symptomatic patients in the early stage of infection.
- Open Access
Long COVID Syndrome Prevalence in 2025 in an Integral Healthcare Consortium in the Metropolitan Area of Barcelona: Persistent and Transient Symptoms
Background: Long COVID can persist for years, but little is known about its prevalence in relation to the number of infections. This study examines the prevalence of long COVID in association with the number of infections and vaccination status. Methods: We analyzed anonymized data on long COVID cases, thrombotic events and polypharmacy from March 2020, provided by the Data Analysis Control Department for the population assigned to the CST (192,651 at March 2025). Additionally, we analyzed responses to a long COVID symptom-specific survey distributed in March 2024 to individuals aged 18 to 75 years from the CST population diagnosed with COVID-19 as of December 2023 (n = 43,398; 3227 respondents). Symptomatic patients suspected of having long COVID underwent blood tests to exclude alternative diagnoses. Results: The overall detected prevalence of long COVID was 2.4‰, with higher frequency among women aged 30–59 years (p < 0.001). The survey, combined with specific blood tests, improved detection rates by 26.3%. Long COVID prevalence was 3–10 times higher in individuals with three or more infections than in those with only one recorded infection (based on survey/CST data, respectively). The absolute number of thrombotic events among individuals aged >60 doubled from 2020 to 2024, occurring in both vaccinated and unvaccinated individuals, as well as in those with or without prior documented COVID-19 infection, including in patients without chronic treatments. Conclusions: We found a link between SARS-CoV-2 reinfection and long COVID, and a post-pandemic rise in thrombotic events across all populations, regardless of vaccination or prior infection. Findings support continued COVID-19 diagnosis in suspected cases and mask use by healthcare workers treating respiratory patients.
Open AccessLong COVID Syndrome Prevalence in 2025 in an Integral Healthcare Consortium in the Metropolitan Area of Barcelona: Persistent and Transient Symptoms
Background: Long COVID can persist for years, but little is known about its prevalence in relation to the number of infections. This study examines the prevalence of long COVID in association with the number of infections and vaccination status. Methods: We analyzed anonymized data on long COVID cases, thrombotic events and polypharmacy from March 2020, provided by the Data Analysis Control Department for the population assigned to the CST (192,651 at March 2025). Additionally, we analyzed responses to a long COVID symptom-specific survey distributed in March 2024 to individuals aged 18 to 75 years from the CST population diagnosed with COVID-19 as of December 2023 (n = 43,398; 3227 respondents). Symptomatic patients suspected of having long COVID underwent blood tests to exclude alternative diagnoses. Results: The overall detected prevalence of long COVID was 2.4‰, with higher frequency among women aged 30–59 years (p < 0.001). The survey, combined with specific blood tests, improved detection rates by 26.3%. Long COVID prevalence was 3–10 times higher in individuals with three or more infections than in those with only one recorded infection (based on survey/CST data, respectively). The absolute number of thrombotic events among individuals aged >60 doubled from 2020 to 2024, occurring in both vaccinated and unvaccinated individuals, as well as in those with or without prior documented COVID-19 infection, including in patients without chronic treatments. Conclusions: We found a link between SARS-CoV-2 reinfection and long COVID, and a post-pandemic rise in thrombotic events across all populations, regardless of vaccination or prior infection. Findings support continued COVID-19 diagnosis in suspected cases and mask use by healthcare workers treating respiratory patients.
- Open Access
- 4 July 2025
- Published by MDPI AG in Preprints.org
Long COVID Syndrome Prevalence in 2025 in an Integral Healthcare Consortium: Persistent and Transient Symptoms
BACKGROUND: Long COVID can persist for years, but little is known about its prevalence in relation to the number of infections. This study examines the prevalence of Long COVID in association with the number of infections and vaccination status. METHODS: We analyzed anonymized data on Long COVID cases and thrombotic events from March 2020, provided by the Data Analysis Control Department for the population assigned to the CST (192,651 at March 2025). Additionally, we evaluated responses from a specific Long COVID symptom survey distributed to the entire CST population (n=1871 respondents). Symptomatic patients suspected of having Long COVID underwent blood tests to exclude alternative diagnoses. RESULTS: The overall detected prevalence of Long COVID was 2.4‰, with higher frequency among women aged 30–59 years. The survey, combined with blood test, improved detection rates by 26.3%. Long COVID prevalence was 3-10 times higher in individuals with three or more infections than in those with only one recorded infection (based on survey/CST data, respectively). The absolute number of thrombotic events doubled from 2020 to 2024 (p<0.0000001), occurring in both vaccinated and unvaccinated individuals, as well as in those with prior COVID-19 infection. CONCLUSION: Our findings demonstrate a link between SARS-CoV-2 reinfection and Long COVID prevalence. Furthermore, we observed a significant post-pandemic increase in thrombotic events across all populations, regardless of vaccination status or documented prior COVID-19 infection. Results suggest that COVID diagnosis should continue in suspected cases and that healthcare workers attending respiratory patients should continue wearing protective masks.
- 4 July 2025
- Published by MDPI AG in Preprints.org
Open AccessLong COVID Syndrome Prevalence in 2025 in an Integral Healthcare Consortium: Persistent and Transient Symptoms
BACKGROUND: Long COVID can persist for years, but little is known about its prevalence in relation to the number of infections. This study examines the prevalence of Long COVID in association with the number of infections and vaccination status. METHODS: We analyzed anonymized data on Long COVID cases and thrombotic events from March 2020, provided by the Data Analysis Control Department for the population assigned to the CST (192,651 at March 2025). Additionally, we evaluated responses from a specific Long COVID symptom survey distributed to the entire CST population (n=1871 respondents). Symptomatic patients suspected of having Long COVID underwent blood tests to exclude alternative diagnoses. RESULTS: The overall detected prevalence of Long COVID was 2.4‰, with higher frequency among women aged 30–59 years. The survey, combined with blood test, improved detection rates by 26.3%. Long COVID prevalence was 3-10 times higher in individuals with three or more infections than in those with only one recorded infection (based on survey/CST data, respectively). The absolute number of thrombotic events doubled from 2020 to 2024 (p<0.0000001), occurring in both vaccinated and unvaccinated individuals, as well as in those with prior COVID-19 infection. CONCLUSION: Our findings demonstrate a link between SARS-CoV-2 reinfection and Long COVID prevalence. Furthermore, we observed a significant post-pandemic increase in thrombotic events across all populations, regardless of vaccination status or documented prior COVID-19 infection. Results suggest that COVID diagnosis should continue in suspected cases and that healthcare workers attending respiratory patients should continue wearing protective masks.